Skip to content

The value of cardiopulmonary exercise test in diagnosing and prognosing pulmonary hypertension

The value of cardiopulmonary exercise test in diagnosing and prognosing pulmonary hypertension

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OOC-17011025
Enrollment
Unknown
Registered
2017-03-31
Start date
2017-04-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pulmonary arterial hypertension

Interventions

Case series:cardiopulmonary exercise test

Sponsors

Deparment of Pulmonary and Critical Care Medicine, Beijing Anzhen Hospital,Capital Medical University, Beijing Institute of Heart,Lung and Blood Vessel Diseases, Beijing 100029, China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to 80 Years

Inclusion criteria

Inclusion criteria: Continuous observation of 100 cases of anzhen hospital of respiratory and critical care medicine of the PH patients, diagnosis based on the 2015 European heart association/European respiratory disease association pulmonary hypertension guidelines

Exclusion criteria

Exclusion criteria: 1. Age<14 years old; 2. Serious cardiac insufficiency, heart function NYHA class IV, or ejection fraction (EF) of echocardiographic <30%; 3. Repeated syncope or severe haemoptysis; 4. Hemodynamic instability, such as low blood pressure, cardiac arrhythmia, etc.

Design outcomes

Primary

MeasureTime frame
Left heart correlation CPET cardiopulmonary reserve features of PH;

Secondary

MeasureTime frame
CPET cardiopulmonary reserve features of PH;

Countries

China

Contacts

Public ContactYuanxing Wu

Deparment of Pulmonary and Critical Care Medicine, Beijing Anzhen Hospital,Capital Medical University, Beijing Institute of Heart,Lung and Blood Vessel Diseases, Beijing 100029, China

ttyywyx321@163.com+86 010-64456922

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026